Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055201 | 0.86 | RXRA (0.46) | RXRARXRBKMT2AMEN1ACHE | |
| SCHEMBL29699116 | 0.85 | MEN1 (0.45) | KMT2AMEN1UGT2B7ACHEPTGS1 | |
| SCHEMBL15943226 | 0.85 | MEN1 (0.45) | KMT2AMEN1UGT2B7ACHEPTGS1 | |
| SCHEMBL6912468 | 0.83 | PTGS1 (0.58) | KMT2AMEN1UGT2B7ACHEPTGS1 | |
| SCHEMBL2737262 | 0.83 | KDM4E (0.49) | RXRARXRBKMT2AMEN1ACHE | |
| SCHEMBL6912472 | 0.83 | PTGS1 (0.58) | KMT2AMEN1UGT2B7ACHEPTGS1 | |
| SCHEMBL6204640 | 0.83 | RXRA (0.44) | RXRARXRBKMT2AMEN1ACHE | |
| SCHEMBL2475547 | 0.83 | CYP3A4 (0.58) | KMT2AMEN1UGT2B7ACHEPTGS1 | |
| SCHEMBL6402645 | 0.82 | PTGS1 (0.53) | RXRARXRBKMT2AMEN1ACHE | |
| SCHEMBL6396086 | 0.82 | PTGS1 (0.53) | RXRARXRBKMT2AMEN1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2024160277-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| WO-2014084223-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 (JP) | 2014-06-05 | — | — | WO | disclosed |
| EP-1300381-B1 | Process for preparing optically active alcohols | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-6887820-B1 | For producing optically active secondary alcohols, producing optically active compounds useful for various utilities such as intermediates for synthesizing pharmaceutical agents, liquid crystal materials and agents for optical resolution | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-05-03 | — | — | US | disclosed |
| EP-1300381-A1 | Process for preparing optically active alcohols | Japan Science and Technology Corporation (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6184381-B1 | USEFUL AS INTERMEDIATES FOR SYNTHESIZING PHARMACEUTICAL CHEMICALS, LIQUID CRYSTAL MATERIALS AND AGENTS FOR OPTICAL RESOLUTION, REDUCTION, KETONES TO ALCOHOL, IMINES TO AMINES | JAPAN SCIENCE & TECHNOLOGY CORP. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0916637-A1 | PROCESS FOR PREPARATING OPTICALLY ACTIVE COMPOUNDS | Japan Science and Technology Corporation (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | RXRA 101/4885RXRB 57/4885KMT2A 3652/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | RXRA 446/4885RXRB 457/4885KMT2A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.